Apogee Therapeutics (Apogee Therapeutics) Debt-to-EBITDA : -0.01 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apogee Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.14 Mil. Apogee Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.63 Mil. Apogee Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-152.61 Mil. Apogee Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Apogee Therapeutics's Debt-to-EBITDA or its related term are showing as below:

APGE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.02 Med: -0.02 Max: -0.02
Current: -0.02

During the past 2 years, the highest Debt-to-EBITDA Ratio of Apogee Therapeutics was -0.02. The lowest was -0.02. And the median was -0.02.

APGE's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.37 vs APGE: -0.02

Apogee Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Apogee Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics Debt-to-EBITDA Chart

Apogee Therapeutics Annual Data

Trend

Dec22

Dec23

Debt-to-EBITDA

-0.02

Apogee Therapeutics Quarterly Data
	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial			-	-	-	-0.02	-0.01

Competitive Comparison of Apogee Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Apogee Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apogee Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Apogee Therapeutics's Debt-to-EBITDA falls into.

Apogee Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apogee Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.101	+	0.933)	/	-83.985
	=	-0.02

Apogee Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.141	+	0.63)	/	-152.608
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Apogee Therapeutics (NAS:APGE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Apogee Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Apogee Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Apogee Therapeutics (Apogee Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453

Website

https://www.apogeetherapeutics.com

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.

Executives

Mark C. Mckenna	director	400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Nimish P Shah	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jane Henderson	officer: Chief Financial Officer	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr	director	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Michael Thomas Henderson	director, officer: Chief Executive Officer	421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p.	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox	director	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener	director	3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Carl Dambkowski	officer: Chief Medical Officer	221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453